163 related articles for article (PubMed ID: 26917483)
1. [Effect and regulation of metformin on endometrial carcinoma subline of progestin-resistance].
Niu YJ; Shi HR; Xie Y
Zhonghua Fu Chan Ke Za Zhi; 2016 Feb; 51(2):135-40. PubMed ID: 26917483
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
3. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
Zhao SJ; Chen XJ; Feng YJ
Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
5. [Study of mechanism of medroxyprogesterone 17-acetate on the cancer stem cell-like properties of human endometrial cancer].
Liu BJ; Li XP; Zhao LJ; Wang JL; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2013 Oct; 48(10):772-7. PubMed ID: 24406136
[TBL] [Abstract][Full Text] [Related]
6. [Research of the influence and mechanism about metformin on the proliferation of differentiated endometrial carcinoma cells].
Wang J; Shi H; Xie Y; Peng Z
Zhonghua Fu Chan Ke Za Zhi; 2015 Sep; 50(9):685-91. PubMed ID: 26675396
[TBL] [Abstract][Full Text] [Related]
7. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor gene expression in human endometrial adenocarcinoma cells: regulation by progestins.
Gong Y; Anzai Y; Murphy LC; Ballejo G; Holinka CF; Gurpide E; Murphy LJ
Cancer Res; 1991 Oct; 51(20):5476-81. PubMed ID: 1833051
[TBL] [Abstract][Full Text] [Related]
9. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
10. Response-specific progestin resistance in a newly characterized Ishikawa human endometrial cancer subcell line resulting from long-term exposure to medroxyprogesterone acetate.
Zhao S; Li G; Yang L; Li L; Li H
Oncol Lett; 2013 Jan; 5(1):139-144. PubMed ID: 23255909
[TBL] [Abstract][Full Text] [Related]
11. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression.
Zhang Z; Dong L; Sui L; Yang Y; Liu X; Yu Y; Zhu Y; Feng Y
Int J Gynecol Cancer; 2011 Feb; 21(2):213-21. PubMed ID: 21270604
[TBL] [Abstract][Full Text] [Related]
12. Metformin attenuates the production and proliferative effects of prolactin induced by medroxyprogesterone acetate during fertility-sparing treatment for endometrial cancer.
Gu W; Mitsuhashi A; Kobayashi T; Shozu M
BMC Cancer; 2022 Jul; 22(1):753. PubMed ID: 35820883
[TBL] [Abstract][Full Text] [Related]
13. [Effects of metformin on the estrogen-induced proliferation and the expression of ER in human endometrial cancer cells].
Zhang J; Zhang B; Yin Z; Chen F; Liu T; Xu H; Liu Y; Zhou X
Zhonghua Fu Chan Ke Za Zhi; 2014 Dec; 49(12):932-7. PubMed ID: 25608995
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone acetate causes the alterations of endoplasmic reticulum related mRNAs and lncRNAs in endometrial cancer cells.
Cao W; Gao W; Zheng P; Sun X; Wang L
BMC Med Genomics; 2019 Nov; 12(1):163. PubMed ID: 31718641
[TBL] [Abstract][Full Text] [Related]
16. Roles of SIRT1/FoxO1/SREBP-1 in the development of progestin resistance in endometrial cancer.
Wang Y; Zhang L; Che X; Li W; Liu Z; Jiang J
Arch Gynecol Obstet; 2018 Nov; 298(5):961-969. PubMed ID: 30206735
[TBL] [Abstract][Full Text] [Related]
17. Enhanced c-jun activity alters responsiveness to medroxyprogesterone acetate in Ishikawa human endometrial carcinoma cells.
Alkhalaf M; Murphy LJ; Murphy LC
Mol Endocrinol; 1993 Dec; 7(12):1634-41. PubMed ID: 8145769
[TBL] [Abstract][Full Text] [Related]
18. 5-aza-2'-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy.
Hu Q; Yu L; Chen R; Wang YL; Ji L; Zhang Y; Xie Y; Liao QP
Int J Gynecol Cancer; 2012 Jul; 22(6):951-9. PubMed ID: 22683940
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of metformin and medroxyprogesterone 17‑acetate on the development of endometrial cancer.
Mu N; Dong M; Li L; Xia M; Qv L; Wang Y; Dong C; Chen Y; Zuo Y; Hou J; Xue F
Oncol Rep; 2018 Apr; 39(4):2015-2021. PubMed ID: 29393479
[TBL] [Abstract][Full Text] [Related]
20. MET Inhibits the Proliferation of EC Cells by Increasing MPA Sensitivity.
Sun F; Zhou J; Hao Y; Kuang L; Zhang B
Altern Ther Health Med; 2023 Jul; 29(5):334-341. PubMed ID: 37171945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
